Claim Missing Document
Check
Articles

Found 10 Documents
Search

In vitro transcription of HIV-1 RNA for standard RNA Yasmon, Andi; Bela, Budiman; Ibrahim, Fera; Syahruddin, Elisna
Medical Journal of Indonesia Vol 20, No 3 (2011): August
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (119.131 KB) | DOI: 10.13181/mji.v20i3.447

Abstract

Background: The quantitative assays are important tests in the management of patients with HIV-1/AIDS. The important step in developing the assay is the availability of the standard HIV-1 RNA. For this purpose, we optimized in vitro HIV-1 RNA transcription to produce the standard HIV-1 RNA.Methods: The HIV-1 DNA was amplified from pNL43 by PCR using a primer pair that was specific for conserved region of HIV-1 Gag gene. The PCR product was further cloned into pBluescript II KS. The recombinant plasmid was restricted with EcoRI enzyme. Then, the linearized plasmid was used as template for RNA transcription. RT-PCR and PCR were performed simultaneously for confirmation of synthesized RNA fragment.Results: A 115 bp DNA of HIV-1 Gag gene has been cloned into pBluescript II SK with the exact true orientation. The reaction of the RNA transcription was also successfully performed. The RNA transcripts have been confirmed and showed the accuracy of the transcripts.Conclusion: We successfuly constructed the recombinant plasmid containing a conserved region of HIV-1 Gag gene, and the HIV-1 RNA has been transcribed in vitro as well. (Med J Indones. 2011; 20:185-9)Keywords: HIV-1/AIDS, Quantitative assay, RNA transcription
Gejala Klinis Neurologis dan Gambaran CT Scan Otak Pasien Kanker Paru Karsinoma Bukan Sel Kecil Metastasis ke Otak di Rumah Sakit Persahabatan YULIANTI, DIAN; SYAHRUDDIN, ELISNA; HUDOYO, AHMAD; ICKSAN, AZIZA
Indonesian Journal of Cancer Vol 4, No 1 (2010): Jan - Mar 2010
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Brain is one of the common sites of distant metastasis in patients of lung cancer, and incidens of brain metastasis in lung cancer is considered high. In Non-small Cell lung cancer guide line, brain CT done if the neurological symptom occured. Therefore analysis of diagnostic approach related to brain metastases is needed. Prospective analysis of 35 patients newly diagnosed cases of brain metastases in NSCLC. Cross sectional study with additional analysis to find relationship of clinical symptom to result of CT brain over periode July 2008-August 2009 in Persahabatan Hospital. Data were analysed as regards to the presence/absence of neurogical symtomps. Prognostic approach was applied to analyze survival rate.We found that 85,7% patients brain metastases with neurological symptomatic and 14,3% asymptomatic. Five (14,3%) patients with more than one neurologycal symptoms. Depend on stage and cell type of which 27 (77,1%) with adenocarcinoma, 21 (62,9%) with T4, 17 (48,6%) N0 and patients with soliter nodule 8 (22,9%). There’s no correlation between neurologycal symptom and brain metastases. Median survival time of lung cancer patients with brain metastases are 11 month. The majority lung cancer patients with brain metastasis have neurological symptoms. The most brain metatases found in patient with adenocarcinoma, T4 and N0. Median survival was increased in treated patients Keywords: Lung cancer, NSCLC, Brain metastases, Neurological symptoms
Radiology Appearance of Malignant Peripheral Nerve Sheath Tumor: a Case Report Icksan, Aziza G; Simargi, Yopi; Syahruddin, Elisna; Hidajat, Heriawaty
Indonesian Journal of Cancer Vol 3, No 4 (2009): Oct - Dec 2009
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (396.632 KB)

Abstract

Malignant peripheral nerve sheath tumor (MPNST) merupakan sarkoma jaringan lunak yang jarang. Tumor ini meliputi MPNST sampai 10% dari 1-2 per 100.000 populasi/tahun kasus sarkoma jaringan lunak. Makalah ini memaparkan kasus MPNST yang ditemukan di permukaan tubuh, yaitu kepala bagian frontal, temporal, parietal kanan, leher, lengan kiri, torso, dan di organ-organ dalam yaitu otak, paru-paru, hepar, ginjal kanan, intraabdomen kiri, dan tanpa terkait dengan neurofibromatosis tipe 1 (NF1) serta tanpa riwayat terapi radiasi. Pasien hanya mengeluh sakit pada benjolan di punggung. Gambaran computed tomography (CT) otak ditemukan massa jaringan lunak di subkutis frontal dan parietal, serta lesi hipodens di serebri frontal yang menyangat di perifer setelah pemberian kontras dicurigai ke arah keganasan. Pada foto toraks dan CT paru ditemukan nodul multipel. Tampak pula massa pada ginjal kanan dan massa intrabdomen kiri. Massa heterogen pada hepar lobus kiri ditemukan pada ultrasonografi abdomen. Pemeriksaan histologi memastikan diagnosis MPNST. Pasien ini direncanakan untuk perawatan paliatif.Kata kunci: Radiologi. MPNST, sarkoma
Ekspresi Protein Gen p53 yang Bermutasi pada Jaringan Sediaan Blok Parafin Kanker Paru Karsinoma Bukan Sel Kecil HANAFI, ARIF R; SYAHRUDDIN, ELISNA; HUDOYO, AHMAD
Indonesian Journal of Cancer Vol 4, No 3 (2010): Jul - Sep 2010
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The tumor supressor gen p53 mutation encodes a protein that inhibits programmed cell death (apoptosis). The protein is expressed in basal cells in normal human epithelium, but no data are available on the frequency or clinical importance of its expression in carcinoma. We studied p53 mutation protein expression in post surgery tissues of patients with non-small cell lung carcinoma (NSCLC) and evaluated the correlation between protein expressions with prognosis of diseases. We have performed a retrospective study using 43 parafin block samples of NSCLC patients who were underwent surgery in Persahabatan Hospital during 1997 to 2008. The p53 mutation protein expression were analyzed by immunohystochemical method using a monoclonal antibody specific for p53 mutation protein. The possibility that p53 mutation expression correlated with survival was investigated with the log-rank test Kaplan Meier. Patients characteristic we found male 25/43 (58.1%) female 18/43 (41.9%) with mean age 56.19 + 8.3 y.o and mostly age 40 to 60 y.o 33/43 (76.7%). Number of smoker patiens were 31/43 (72.1%). We also detected p53 mutation protein in 16/43 (37,2%) in NSCLC tissues. Regarding histopatology types were 9/18 (50%) in squamous-cell carcinomas and 7/25 (28%) in adenocarcinomas. The corellation between positive p53 mutation protein expressions with pathological staging was significant p 0,004, according to T status T1-T2 62,5% and T3-T4 23,8% have had positive p53 mutation protein. Favorable prognostic significance of p53 mutation in patients with NSCLC stage I – II, patients in the positive p53 mutataion survived longer than those in negative with respective median survival durations 28 and 18 months p 0,019. Adenocarcinomas type with p53 mutation have had median survival 11 months compared with squamose cell carcinomas 14 months.
The accuracy of Aziza’s scoring system in limited slice non-enhanced thoracic CT for the diagnosis of adult pulmonary tuberculosis Icksan, Aziza; Faisal, Arif; Syahruddin, Elisna
Medical Journal of Indonesia Vol 26, No 1 (2017): March
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (468.852 KB) | DOI: 10.13181/mji.v26i1.1432

Abstract

Background: Tuberculosis (TB) is still a major cause of morbidity and mortality in Indonesia. Thus, a fast and accurate method in diagnosing pulmonary TB (PTB) is needed, especially in adult smear-negative-TB cases. The purpose of this study was to determine the accuracy of a novel scoring system (Aziza’s score) using clinical data and characteristic abnormalities that are found in the limited slice non-enhanced thoracic CT.Methods: This was a prospective cross-sectional study. A limited slice non-enhanced thoracic CT was performed to establish a diagnosis of PTB in patients with suspected PTB and to assess the diagnostic value of the scoring system. A reference standard used in this study was the clinical expertise of two pulmonologists. The scoring system was analyzed using bivariate and multivariate Cox regression analysis.Results: 84 of 130 suspected PTB patients were diagnosed as PTB. They were diagnosed based on pulmonary characteristic abnormalities that were found in the limited slice non-enhanced thoracic CT. The scoring system was analyzed using bivariate and multivariate Cox regression analysis. The total scores which were equal to or more than 29 could diagnose PTB with the accuracy of 96.1% (95% CIs=91.3–98.3), sensitivity of 96.5% (95% CIs=90.1–98.8), and specificity of 95.6% (95% CIs=90.1–98.8), This novel scoring method was name as an Aziza’s scoring system.Conclusion: Aziza’s scoring system performed in the limited slice non-enhanced thoracic CT has a higher accuracy compared to the reference standard for the diagnosis of adult PTB.
Masalah Kanker Paru pada Usia Lanjut Putra, Andika Chandra; Nurwidya, Fariz; Andarini, Sita; Zaini, Jamal; Syahruddin, Elisna; Hudoyo, Ahmad; Jusuf, Anwar
Cermin Dunia Kedokteran Vol 42, No 11 (2015): Kanker
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (130.087 KB) | DOI: 10.55175/cdk.v42i11.948

Abstract

Kanker paru masih menjadi masalah kesehatan yang sulit diatasi bukan saja karena meningkatnya jumlah perokok di Indonesia tetapi juga disebabkan tingginya mortalitas dan morbiditas penderita. Beberapa panduan pengobatan merekomendasikan penanganan multimodalitas. Tatalaksana kanker paru cenderung tidak optimal pada usia lanjut padahal hampir separuh penderita kanker paru berusia di atas 65 tahun. Pasien kanker paru berusia lanjut sering memiliki penyakit komorbid, status tampilan buruk serta risiko toksisitas terapi tinggi. Tulisan ini merupakan tinjauan pustaka tatalaksana kanker paru pada usia lanjut.Lung cancer remains a health problem in Indonesia because of increase of young smokers and its high mortality and morbidity. There is a tendency of inadequate management of lung cancer among elderly patients despite fact that almost half of lung cancer patients aged over 65 years. Lung cancer management is still challenging and need comprehensive approach since older patients are more likely to have decreased functional reserve which limit their ability to undergo surgery or receive chemotherapy. Several guidelines recommended multimodality treatment. Ageing is also associated with increased co-morbid medical conditions that could exacerbate and influence outcome. This article will discuss treatment of lung cancer in elderlies.
Gejala Klinis Neurologis dan Gambaran CT Scan Otak Pasien Kanker Paru Karsinoma Bukan Sel Kecil Metastasis ke Otak di Rumah Sakit Persahabatan DIAN YULIANTI; ELISNA SYAHRUDDIN; AHMAD HUDOYO; AZIZA ICKSAN
Indonesian Journal of Cancer Vol 4, No 1 (2010): Jan - Mar 2010
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v4i1.78

Abstract

Brain is one of the common sites of distant metastasis in patients of lung cancer, and incidens of brain metastasis in lung cancer is considered high. In Non-small Cell lung cancer guide line, brain CT done if the neurological symptom occured. Therefore analysis of diagnostic approach related to brain metastases is needed. Prospective analysis of 35 patients newly diagnosed cases of brain metastases in NSCLC. Cross sectional study with additional analysis to find relationship of clinical symptom to result of CT brain over periode July 2008-August 2009 in Persahabatan Hospital. Data were analysed as regards to the presence/absence of neurogical symtomps. Prognostic approach was applied to analyze survival rate.We found that 85,7% patients brain metastases with neurological symptomatic and 14,3% asymptomatic. Five (14,3%) patients with more than one neurologycal symptoms. Depend on stage and cell type of which 27 (77,1%) with adenocarcinoma, 21 (62,9%) with T4, 17 (48,6%) N0 and patients with soliter nodule 8 (22,9%). Theres no correlation between neurologycal symptom and brain metastases. Median survival time of lung cancer patients with brain metastases are 11 month. The majority lung cancer patients with brain metastasis have neurological symptoms. The most brain metatases found in patient with adenocarcinoma, T4 and N0. Median survival was increased in treated patients Keywords: Lung cancer, NSCLC, Brain metastases, Neurological symptoms
Ekspresi Protein Gen p53 yang Bermutasi pada Jaringan Sediaan Blok Parafin Kanker Paru Karsinoma Bukan Sel Kecil ARIF R HANAFI; ELISNA SYAHRUDDIN; AHMAD HUDOYO
Indonesian Journal of Cancer Vol 4, No 3 (2010): Jul - Sep 2010
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v4i3.101

Abstract

The tumor supressor gen p53 mutation encodes a protein that inhibits programmed cell death (apoptosis). The protein is expressed in basal cells in normal human epithelium, but no data are available on the frequency or clinical importance of its expression in carcinoma. We studied p53 mutation protein expression in post surgery tissues of patients with non-small cell lung carcinoma (NSCLC) and evaluated the correlation between protein expressions with prognosis of diseases. We have performed a retrospective study using 43 parafin block samples of NSCLC patients who were underwent surgery in Persahabatan Hospital during 1997 to 2008. The p53 mutation protein expression were analyzed by immunohystochemical method using a monoclonal antibody specific for p53 mutation protein. The possibility that p53 mutation expression correlated with survival was investigated with the log-rank test Kaplan Meier. Patients characteristic we found male 25/43 (58.1%) female 18/43 (41.9%) with mean age 56.19 + 8.3 y.o and mostly age 40 to 60 y.o 33/43 (76.7%). Number of smoker patiens were 31/43 (72.1%). We also detected p53 mutation protein in 16/43 (37,2%) in NSCLC tissues. Regarding histopatology types were 9/18 (50%) in squamous-cell carcinomas and 7/25 (28%) in adenocarcinomas. The corellation between positive p53 mutation protein expressions with pathological staging was significant p 0,004, according to T status T1-T2 62,5% and T3-T4 23,8% have had positive p53 mutation protein. Favorable prognostic significance of p53 mutation in patients with NSCLC stage I II, patients in the positive p53 mutataion survived longer than those in negative with respective median survival durations 28 and 18 months p 0,019. Adenocarcinomas type with p53 mutation have had median survival 11 months compared with squamose cell carcinomas 14 months.
Radiology Appearance of Malignant Peripheral Nerve Sheath Tumor: a Case Report Aziza G Icksan; Yopi Simargi; Elisna Syahruddin; Heriawaty Hidajat
Indonesian Journal of Cancer Vol 3, No 4 (2009): Oct - Dec 2009
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (396.632 KB) | DOI: 10.33371/ijoc.v3i4.144

Abstract

Malignant peripheral nerve sheath tumor (MPNST) merupakan sarkoma jaringan lunak yang jarang. Tumor ini meliputi MPNST sampai 10% dari 1-2 per 100.000 populasi/tahun kasus sarkoma jaringan lunak. Makalah ini memaparkan kasus MPNST yang ditemukan di permukaan tubuh, yaitu kepala bagian frontal, temporal, parietal kanan, leher, lengan kiri, torso, dan di organ-organ dalam yaitu otak, paru-paru, hepar, ginjal kanan, intraabdomen kiri, dan tanpa terkait dengan neurofibromatosis tipe 1 (NF1) serta tanpa riwayat terapi radiasi. Pasien hanya mengeluh sakit pada benjolan di punggung. Gambaran computed tomography (CT) otak ditemukan massa jaringan lunak di subkutis frontal dan parietal, serta lesi hipodens di serebri frontal yang menyangat di perifer setelah pemberian kontras dicurigai ke arah keganasan. Pada foto toraks dan CT paru ditemukan nodul multipel. Tampak pula massa pada ginjal kanan dan massa intrabdomen kiri. Massa heterogen pada hepar lobus kiri ditemukan pada ultrasonografi abdomen. Pemeriksaan histologi memastikan diagnosis MPNST. Pasien ini direncanakan untuk perawatan paliatif.Kata kunci: Radiologi. MPNST, sarkoma
Observational Study of Paclitaxel-Carboplatin versus Pemetrexed-Carboplatin for Advanced Pulmonary Adenocarcinoma at Single-Centre in Indonesia Rianyta Rianyta; Melva Louisa; Elisna Syahruddin; Vivian Soetikno
eJournal Kedokteran Indonesia Vol 9, No. 3 - Desember 2021
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (224.216 KB) | DOI: 10.23886/ejki.9.16.178-86

Abstract

Platinum-based chemotherapy regimens with two types of drugs, such as paclitaxel-carboplatin and pemetrexedcarboplatin, are first-line therapy for pulmonary adenocarcinoma patients with negative epidermal growth factor receptor (EGFR) mutation. This study aimed to determine the efficacy, toxicity, and cost profile of paclitaxel-carboplatin compared to pemetrexed-carboplatin. This is a cross-sectional study. Pulmonary adenocarcinoma negative EGFR mutation naïve patients treated with paclitaxel-carboplatin or pemetrexed-carboplatin were included. Effectiveness was assessed based on the overall response rate (ORR) according to the response evaluation criteria in solid tumours (RECIST). A pharmacoeconomic analysis is performed based on clinical outcomes consisting of effectiveness and direct medical costs. Medical records from 21 patients with paclitaxel-carboplatin and 21 patients with pemetrexedcarboplatin were successfully evaluated. The effectiveness of the two chemotherapy regimens was not significantly different (OR, 1.25; 95% confidence interval, 0.34 to 4.64; p = 0.739). Frequent haematological toxicities experienced in the two groups were grade 1-2 anaemia, neutropenia, leukopenia. Grade 3 anaemia, leukopenia, and neutropenia were more common in the paclitaxel-carboplatin group. The two groups’ nonhematological toxicities were nausea vomitus and hair loss, with peripheral neuropathy more experienced by the paclitaxel-carboplatin group. Costminimization analysis reveals that the average cost per patient with pulmonary adenocarcinoma negative EGFR mutation with paclitaxel-carboplatin regimen was cheaper IDR 10,986,257.55 or 50.25%, compared to pemetrexedcarboplatin. In conclusion, there was no significant difference in the effectiveness of the two regimens. The most common adverse effects in both regimens were haematological toxicities. The average cost per patient with a paclitaxel-carboplatin regimen was cheaper compared to pemetrexed-carboplatin.